Gossamer Bio (NASDAQ:GOSS) Price Target Raised to $10.00

Gossamer Bio (NASDAQ:GOSS – Free Report) had its target price increased by HC Wainwright from $5.00 to $10.00 in a report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($1.12) EPS, […]

Related Keywords

United States ,Bryan Giraudo ,Gossamer Bio Company Profile ,Principal Financial Group Inc ,Securities Exchange Commission ,Acadian Asset Management ,Gossamer Bio Inc ,Vanguard Personalized Indexing Management ,Td Asset Management Inc ,Topco Ltd ,Gossamer Bio ,Free Report ,Bio Trading Down ,Get Free Report ,Exchange Commission ,Financial Group ,Management Inc ,Asset Management ,Tyrosine Kinase ,Gossamer Bio Daily ,Nasdaq Goss ,Goss ,Medical ,Boost Price Target ,Hc Wainwright ,